Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

B. H. L. Harris; J. L. Walsh; R. Neciunaite; P. Manders; A. Cooper; P. De Souza

doi:10.1111/ced.13302

Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

B. H. L. Harris, J. L. Walsh, R. Neciunaite, P. Manders, A. Cooper, P. De Souza

Western Sydney University

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Kaposi sarcoma (KS) is an angioproliferative disorder caused by the gammaherpesvirus: human herpesvirus (HHV-8), also known as the Kaposi sarcoma-associated herpesvirus (KSHV).1 HHV-8 causes four subtypes of KS: acquired immunodeficiency syndrome-related (epidemic) KS [the most common], Mediterranean (classic) KS, African (endemic) KS and iatrogenic KS [related to medically induced immunosuppression].

Original language	English
Pages (from-to)	234-236
Number of pages	3
Journal	Clinical and Experimental Dermatology
Volume	43
Issue number	2
DOIs	https://doi.org/10.1111/ced.13302
Publication status	Published - 2018

Keywords

Kaposi's sarcoma
inhibitors
protein-tyrosine kinase

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ced.13302

Fingerprint

Dive into the research topics of 'Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy'. Together they form a unique fingerprint.

Cite this

Harris, B. H. L., Walsh, J. L., Neciunaite, R., Manders, P., Cooper, A., & De Souza, P. (2018). Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. Clinical and Experimental Dermatology, 43(2), 234-236. https://doi.org/10.1111/ced.13302

@article{dec45290c4ea430d9b72288e3088f516,

title = "Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy",

abstract = "Kaposi sarcoma (KS) is an angioproliferative disorder caused by the gammaherpesvirus: human herpesvirus (HHV-8), also known as the Kaposi sarcoma-associated herpesvirus (KSHV).1 HHV-8 causes four subtypes of KS: acquired immunodeficiency syndrome-related (epidemic) KS [the most common], Mediterranean (classic) KS, African (endemic) KS and iatrogenic KS [related to medically induced immunosuppression].",

keywords = "Kaposi's sarcoma, inhibitors, protein-tyrosine kinase",

author = "Harris, {B. H. L.} and Walsh, {J. L.} and R. Neciunaite and P. Manders and A. Cooper and {De Souza}, P.",

year = "2018",

doi = "10.1111/ced.13302",

language = "English",

volume = "43",

pages = "234--236",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Wiley-Blackwell Publishing",

number = "2",

}

Harris, BHL, Walsh, JL, Neciunaite, R, Manders, P, Cooper, A & De Souza, P 2018, 'Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy', Clinical and Experimental Dermatology, vol. 43, no. 2, pp. 234-236. https://doi.org/10.1111/ced.13302

Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. / Harris, B. H. L.; Walsh, J. L.; Neciunaite, R. et al.
In: Clinical and Experimental Dermatology, Vol. 43, No. 2, 2018, p. 234-236.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

AU - Harris, B. H. L.

AU - Walsh, J. L.

AU - Neciunaite, R.

AU - Manders, P.

AU - Cooper, A.

AU - De Souza, P.

PY - 2018

Y1 - 2018

N2 - Kaposi sarcoma (KS) is an angioproliferative disorder caused by the gammaherpesvirus: human herpesvirus (HHV-8), also known as the Kaposi sarcoma-associated herpesvirus (KSHV).1 HHV-8 causes four subtypes of KS: acquired immunodeficiency syndrome-related (epidemic) KS [the most common], Mediterranean (classic) KS, African (endemic) KS and iatrogenic KS [related to medically induced immunosuppression].

AB - Kaposi sarcoma (KS) is an angioproliferative disorder caused by the gammaherpesvirus: human herpesvirus (HHV-8), also known as the Kaposi sarcoma-associated herpesvirus (KSHV).1 HHV-8 causes four subtypes of KS: acquired immunodeficiency syndrome-related (epidemic) KS [the most common], Mediterranean (classic) KS, African (endemic) KS and iatrogenic KS [related to medically induced immunosuppression].

KW - Kaposi's sarcoma

KW - inhibitors

KW - protein-tyrosine kinase

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:45496

U2 - 10.1111/ced.13302

DO - 10.1111/ced.13302

M3 - Article

SN - 0307-6938

VL - 43

SP - 234

EP - 236

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 2

ER -

Harris BHL, Walsh JL, Neciunaite R, Manders P, Cooper A , De Souza P. Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. Clinical and Experimental Dermatology. 2018;43(2):234-236. doi: 10.1111/ced.13302

Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this